drugset / Trial / NCT00154167

Safety and Efficacy Study of NV-101 in Dental Patients

NCT00154167

Phase 2 Completed 122 enrolled Novalar Pharmaceuticals, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study was: * to determine if NV-101 accelerates recovery from numbness compared to placebo * to evaluate safety of NV-101

Timeline

Start
2003-02
Primary completion
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentolamine Small molecule 1.8 ml Other

Indications

No indication recorded.